Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06384261
Title A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors OncoVerity, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | DEU | CHE


No variant requirements are available.